Gulf Medical University (GMU) in Ajman is now offering a PhD programme in precision medicine (PhD PM), in collaboration with the University of Paris Saclay, France.
The new PhD PM programme — by the GMU’s College of Medicine and Thumbay Research Institute for Precision Medicine (TRIPM) — has been accredited by the Commission for Academic Accreditation of the UAE’s Ministry of Education.
“This PhD is a dual degree programme in collaboration with Paris-Saclay University, France. We have joined hands to promote international exchanges, increase scientific cooperation and development of research…and provide value to the community by also giving priority to UAE nationals for this programme. In 2020, the University of Paris Saclay has been ranked as the No. 1 university in France, sixth in Europe and 14th in the world,” said professor Hossam Hamdy, chancellor of GMU.
The dual PhD programme in precision medicine primarily aims to develop and support scientists and researchers who seek to study and explore this changing field of healthcare.
Precision medicine involves the application of omics sciences and systems biology to understand the causes of a patient’s disease at the molecular level. Then, the information is used to design targeted treatments for the individual.
In essence, precision medicine proposes the customisation of healthcare in medical decisions, treatments, or products tailored to the individual or group of patients — instead of one-drug-fits-all models.
Professor Salem Chouaib, director of the PhD programme added: “The GMU Strategic Plan had identified precision medicine research as its main research direction. This led to the development of the TRIPM, with a research agenda focusing on understanding the molecular, genetic and immunological basis of cancer, diabetics and cardiovascular diseases. The Doctorate School of Oncology Health at Paris Saclay will host the students in more than 100 specialised labs.”
Under the programme, the candidate will receive two PhD degrees: PhD in Precision Medicine awarded by GMU and PhD in Cancer, Biology, Medicine, Health awarded by Paris-Saclay University.
A multi-disciplinary team of medics from India and the UAE will jointly establish a multi-organ transplant centre in Abu Dhabi — only the second such facility in the emirate — offering solace to patients waiting for an organ transplant in the UAE.
The centre will be based at VPS Healthcare’s Burjeel Medical City at Mohammed Bin Zayed City in Abu Dhabi. It will have a multi-disciplinary team led by Dr Sandeep Attawar, Chair and Director of KIMS Institute for Heart and Lung Transplantation in Hyderabad, India.
Burjeel Hospitals CEO John Sunil and Dr Attawar inked the memorandum of understanding for the medical collaboration.
As per the agreement, Burjeel Medical City will set up a state-of-the-art organ transplant centre with advanced technology and equipment for diagnosis, treatment and care. Meanwhile, KIMS Hospital will support by sharing their medical expertise and knowledge in treating the patients.
Dr Attawar’s team will introduce all programmes with regard to heart and liver transplantation. A first-of-its-kind department to deal with the management of heart failures in children will be set up too.
The medical team will be led by Dr Attawar, who is also the founding director of the solid thoracic organ transplant programme at KIMS Hospitals, and has performed almost 280 thoracic organ transplants, including 160 double lung transplants, 88 heart transplants, and 32 combined heart and lung transplants.
The team has performed around 12 double lung transplants on patients with end-stage Covid-19-damaged lungs.
Sunil noted: “In the initial phase, we will be concentrating on setting up the infrastructure for heart and lung transplants. Soon, we will strengthen our organ transplant centre and open directly to patients in need.”
Dr Attawar added: “We will be supporting Burjeel Medical City by extending our expertise in multi-organ transplants. Our team at KIMS has recently conducted 12 Covid double lung transplants in Hyderabad and has successfully conducted hundreds of other organ transplant cases. We firmly believe and look forward to serving the patients in the UAE through this partnership and translate this opportunity for the overall benefit of the health sector in the Middle East.”
May the New Year brings you Health and Happiness!
The state-of-the-art biochemistry laboratory is located at Dubai Hospital.
A smart biochemistry laboratory — equipped with artificial intelligence solutions and high-speed devices — was inaugurated at Dubai Hospital on Tuesday.
With its advanced technologies, the first-of-its-kind lab of the Dubai Health Authority (DHA) can analyse up to two million samples per year. In less than an hour, one of its machines could test 2,000 samples for liver, kidney and heart functions. Advanced tumour devices could process 300 samples within the same period.
Besides having the latest equipment, experienced doctors and specialists are running the facility, enabling the lab to evaluate some samples and extract results in less than a minute.
The centre, which will function 24/7, will initially cater to Dubai Hospital and all DHA facilities, and plans have been set to eventually include the private sector in the country and the region.
The DHA also aims to establish the new lab as a medical, scientific and research reference centre for education and training purposes.
Humaid Al Qutami, director-general of the DHA said the new lab is considered an important addition to the authority’s international-standard labs, which are equipped with the latest technologies that require minimal human intervention.
It can conduct different types of tests that provide details on the vital functions of the kidneys, heart, liver, tumor markers, hormones, brain and spinal fluids.
The authority has been working hard to modernise its medical facilities and make the most of AI to provide efficient and highly accurate services, Al Qutami said.
During the lab’s inauguration, the DHA chief was briefed on the scope and capabilities of the lab. Among those present at the launch were Dr Younis Kazim, CEO of Dubai Healthcare Cooperation; Dr Farida Al Khaja, CEO of Clinical Support Services and Nursing Sector; Dr Maryam Al Rayes, CEO of Dubai Hospital; Dr Jamal Saleh, Medical director of medicine at Dubai Hospital; and Dr Hussain Al Samt, director of DHA’s pathology and genetics department.